Open AccessA transcriptomic study for identifying cardia‐ and non–cardia‐specific gastric cancer prognostic factors using genetic algorithm‐based methods
Author(s) -
Xin Junyi,
Wu Yanling,
Wang Xiaowei,
Li Shuwei,
Chu Haiyan,
Wang Meilin,
Du Mulong,
Zhang Zhengdong
Publication year - 2020
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.15618
Subject(s) - nomogram , medicine , gastric cardia , proportional hazards model , concordance , cancer , oncology , adenocarcinoma
Gastric cancer (GC) is a heterogeneous tumour with numerous differences of epidemiologic and clinicopathologic features between cardia cancer and non‐cardia cancer. However, few studies were performed to construct site‐specific GC prognostic models. In this study, we identified site‐specific GC transcriptomic prognostic biomarkers using genetic algorithm (GA)‐based support vector machine (GA‐SVM) and GA‐based Cox regression method (GA‐Cox) in the Cancer Genome Atlas (TCGA) database. The area under time‐dependent receive operating characteristic (ROC) curve (AUC) regarding 5‐year survival and concordance index (C‐index) was used to evaluate the predictive ability of Cox regression models. Finally, we identified 10 and 13 prognostic biomarkers for cardia cancer and non‐cardia cancer, respectively. Compared to traditional models, the addition of these site‐specific biomarkers could notably improve the model preference (cardia: AUC traditional vs AUC combined = 0.720 vs 0.899, P = 8.75E‐08; non‐cardia: AUC traditional vs AUC combined = 0.798 vs 0.994, P = 7.11E‐16). The combined nomograms exhibited superior performance in cardia and non‐cardia GC survival prediction (C‐index cardia = 0.816; C‐index noncardia = 0.812). We also constructed a user‐friendly GC site‐specific molecular system (GC‐SMS, https://njmu‐zhanglab.shinyapps.io/gc_sms/ ), which is freely available for users. In conclusion, we developed site‐specific GC prognostic models for predicting cardia cancer and non‐cardia cancer survival, providing more support for the individualized therapy of GC patients.